Citations

Clear

390 citation(s) found for "Loftus, E".

S0664 Disease Control and Changes in Individual Treatment Outcomes From Week 14 to Week 52 With Vedolizumab or Adalimumab in Ulcerative Colitis: A VARSITY Trial Post Hoc Analysis
Lindner, Dirk , Lirio, Richard A. , Agboton, Christian , Loftus, Edward V. , Danese, Silvio , Peyrin‐Biroulet, Laurent , Colombel, Jean‐Frédéric , Sands, Bruce E , Lindner, Dirk, Schreiber, Stefan

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S332-S333

10.14309/01.ajg.0000704704.76894.ca Get It

S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study
Sandborn, William J. , Baert, Filip , Ferrante, Marc , Louis, Édouard , Goteti, Venkata Sasikiran, Mostafa, Nael M., Doan, Thao , Petersson, Joel, Robinson, Anne, Song, Alexandra , D’Haens, Geert , Danese, Silvio , Loftus, Edward V. , Hanauer, Stephen B. , Schreiber, Stefan , Peyrin‐Biroulet, Laurent , Panaccione, Remo , Panés, Julián , Colombel, Jean‐Frédéric , Louis, Edouard , Armuzzi, Alessandro

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S325-S326

10.14309/01.ajg.0000704640.35342.ed Get It

S0644 Tofacitinib for the Treatment of Ulcerative Colitis: An Updated Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
Winthrop, Kevin , Baumgart, Daniel C. , Hart, Ailsa , Alharbi, Othman , Salese, Leonardo , Lawendy, Nervin, Mundayat, Rajiv , Su, Chinyu , Reinisch, Walter , Loftus, Edward V. , Reinisch, Walter

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S323-S323

10.14309/01.ajg.0000704624.79364.8f Get It

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study
D’Haens, Geert , Louis, Édouard , Lacerda, Ana P. , Panés, Julián , Louis, Edouard , Zhou, Qian , Liu, Jianzhong , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S322-S323

10.14309/01.ajg.0000704620.03018.6c Get It

Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota
Bakhshi, Zeinab , Yadav, Siddhant, Salonen, Bradley R. , Bonnes, Sara L. , Varayil, Jithinraj Edakkanambeth , Harmsen, William S. , Tremaine, William J., Loftus, Edward V. , Harmsen, William Scott, Hurt, Ryan T. , Loftus, Edward V , Edakkanambeth Varayil, Jithinraj

Mayo Clinic

Crohn's & Colitis 360 | October 14, 2020 | Volume: 2 | Issue: 4 | Pages: No page available

10.1093/crocol/otaa083 | PMID 34142084 Get It

Abstract Background We sought to estimate the incidence of home parenteral nutrition (HPN) use in a population-based cohort of patients with Crohn disease (CD), and to assess clinical outcomes and complications associated with HPN. Methods We used the Rochester Epidemiology Project (REP) to identify residents of Olmsted County, who were diagnosed with CD between 1970 and 2011, and required HPN. Results Fourteen out of 429 patients (3.3%) with CD received HPN (86% female). Eleven patients (79%) had moderate–severe CD and 12 patients (86%) had fistulizing disease. Thirteen patients (93%) underwent surgery, primarily due to obstruction. Among CD incidence cases, the cumulative incidence of HPN from the date of CD diagnosis was 0% at 1 year, 0.5% at 5 years, 0.8% at 10 years, and 2.4% at 20 years. Indications for HPN included short bowel syndrome in 64%, malnutrition in 29%, and bowel rest in 21%. The median duration of HPN was 2.5 years. There was an average weight gain of 1.2 kg at 6 months, an average weight loss of 1.4 kg at 1 year, and a further weight loss of 2.2 kg at 2 years from the start of HPN. Patients were hospitalized a mean of 5 times after the start of HPN, mainly due to catheter-related bloodstream infections and thrombosis. Conclusions Less than 4% of patients with CD need HPN. Most have moderate to severe disease with short bowel syndrome or malnutrition. Possible reasons for the patients’ weight loss could be noncompliance, and increased metabolic needs because of active disease.
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic
Reinisch, Walter, Danese, Silvio , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Loftus, Edward V , Danese, Silvio , Peyrin-Biroulet, Laurent , Reinisch, Walter

Mayo Clinic

Journal of Crohn's and Colitis | August 7, 2020 | Volume: 14 | Issue: Supplement_3 | Pages: S820-S820

10.1093/ecco-jcc/jjaa138 | PMID 32766822 Get It

Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
Lee, Scott D. , Shivashankar, Raina , Quirk, Daniel, Telliez, Jean-Baptiste, Andrews, John M., Marren, Amy , Loftus, Edward V. , Loftus, Edward V , Zhang, Haiying , Andrews, John, Mukherjee, Arnab

Mayo Clinic

Journal of Clinical Gastroenterology | August 2, 2020 | Volume: 55 | Issue: 3 | Pages: 195-206

10.1097/mcg.0000000000001396 | PMID 32740098 Get It

This article reviews therapeutic drug monitoring (TDM) use for current inflammatory bowel disease (IBD) treatments. IBD comprises Crohn’s disease and ulcerative colitis-chronic gastrointestinal inflammatory disorders. Treatment options for moderate to severe IBD include thiopurines; methotrexate; biologic agents targeting tumor necrosis factor, α4β7 integrin or interleukins 12 and 23; and Janus kinase inhibitors. TDM is recommended to guide treatment decisions for some of these agents. Published literature concerning TDM for IBD treatments was reviewed. S.D.L., R.S., and E.V.L. drew on their clinical experiences. Polymorphisms resulting in altered enzymatic activity inactivating thiopurine metabolites can lead to myelotoxicity and hepatotoxicity. Increased elimination of biologic agents can result from immunogenicity or higher disease activity, leading to low drug concentration and consequent nonresponse or loss of response. TDM may aid treatment and dose decisions for individual patients, based on monitoring metabolite levels for thiopurines, or serum drug trough concentration and antidrug antibody levels for biologic agents. Challenges remain around TDM implementation in IBD, including the lack of uniform assay methods and guidance for interpreting results. The Janus kinase inhibitor tofacitinib is not impacted by enzyme polymorphisms or disease activity, and is not expected to stimulate the formation of neutralizing antidrug antibodies. TDM is associated with implementation challenges, despite the recommendation of its use for guiding many IBD treatments. Newer small molecules with less susceptibility to patient variability factors may fulfill the unmet need of treatment options that do not require TDM, although further study is required to confirm this.
A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy
Bruining, David H. , Faubion, William A. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Fruth, Kristin M. , Harmsen, William S. , Loftus, Edward V. , Fruth, Kristin, Loftus, Edward V , Coelho–Prabhu, Nayantara , Kisiel, John B.

Mayo Clinic

Inflammatory Bowel Diseases | June 12, 2020 | Volume: 27 | Issue: 5 | Pages: 594-602

10.1093/ibd/izaa146 | PMID 32529198 Get It

Abstract Background We sought to compare the dysplasia detection rate of high-definition white light endoscopy (HDWLE) with that of chromoendoscopy in patients with long-standing inflammatory bowel disease (IBD). Methods This is a retrospective observational cohort of patients with IBD who underwent surveillance colonoscopy between October 1, 2016 and September 30, 2017. We assessed the association between dysplasia detection and multiple variables. Results A total of 808 unique colonoscopies were performed, of which 150 (18.6%) included chromoendoscopy. Primary sclerosing cholangitis was a comorbid diagnosis in 24.5% of patients. The performing endoscopist was an IBD specialist with 37.1% of patients and had >10 years’ experience with 64.9% of patients. Prior dysplasia had been seen in 245 (30.3%) patients: 102 (68.0%) and 143 (22.0%) among patients who had chromoendoscopy and HDWLE, respectively. Dysplasia in polyps was found in 129 procedures (15.1%). Among patients who had chromoendoscopy and HDWLE, polypoid dysplasia was identified in 50 (33.0%) and 79 (12.0%) patients, respectively, P < 0.01. Dysplasia in random biopsies was found in 39 patients (4.8%): 15 (10%) who had chromoendoscopy and 24 (3.6%) who had HDWLE (P < 0.001). On multivariate analysis, patient and disease characteristics significantly associated with an increased odds for polypoid dysplasia included older age at diagnosis (odds ratio [OR] = 1.3 per 10 years; 95% confidence interval [CI], 1.07-1.60), having an IBD physician endoscopist (OR = 1.6; 95% CI, 1.01-2.67), having an endoscopist with less than 10 years’ experience (OR = 1.8; 95% CI (1.16-2.89), and prior random dysplasia (OR = 4.2; 95% CI (1.93-9.17). Concomitant primary sclerosing cholangitis was significantly associated with random dysplasia (OR = 2.3; 95% CI, 1.02-5.07). After multivariate analysis adjusting for these variables, chromoendoscopy was no more likely to identify dysplasia than was HDWLE. Conclusions Chromoendoscopy and HDWLE had a similar diagnostic yield for dysplasia detection in patients with chronic IBD-colitis after adjusting for multiple known risk factors.
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic
Reinisch, Walter, Danese, Silvio , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Loftus, Edward V , Danese, Silvio , Peyrin-Biroulet, Laurent

Mayo Clinic

Journal of Crohn's and Colitis | June 5, 2020 | Volume: 14 | Issue: Supplement_3 | Pages: S815-S819

10.1093/ecco-jcc/jjaa119 | PMID 32520311 Get It

Abstract The severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-causing coronavirus disease [COVID]-19 pandemic poses major challenges for patients with inflammatory bowel disease [IBD] to be recruited and maintained in clinical trials. However, clinical trials offer patients who have failed multiple drugs access to study medications with alternative modes of action and the potential for relief from inflammation-mediated symptoms. Therefore, the continuation of clinical trials in IBD during the COVID-19 pandemic is important both for participants and for the community of IBD patients, due to the dire need for an expanded therapeutic armamentarium. As the safety of patients in clinical trials is the leading principle, we are providing ten specific rules to guide patients and principal investigators safely through the challenging time.
PWE-047 Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn’s disease
Louis, Édouard , Cataldi, Fabio, Lacerda, Ana P. , Peyrin‐Biroulet, Laurent , Louis, Edouard , Loftus, Edward V. , Lee, Wen‐Jeng , Ghosh, Subrata

Mayo Clinic

Posters | May 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A195.1-A195

10.1136/gutjnl-2019-bsgabstracts.371 Get It